Vijay Kumar Prajapati
Vijay Kumar Prajapati
Assistant Professor, Central University of Rajasthan
Verified email at curaj.ac.in - Homepage
TitleCited byYear
Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use
S Sundar, A Singh, M Rai, VK Prajapati, AK Singh, B Ostyn, M Boelaert, ...
Clinical infectious diseases 55 (4), 543-550, 2012
1902012
Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes
VK Prajapati, K Awasthi, S Gautam, TP Yadav, M Rai, ON Srivastava, ...
Journal of antimicrobial chemotherapy 66 (4), 874-879, 2011
972011
Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis
V Bhandari, A Kulshrestha, DK Deep, O Stark, VK Prajapati, V Ramesh, ...
PLoS neglected tropical diseases 6 (5), e1657, 2012
862012
Antileishmanial activity of nano-amphotericin B deoxycholate
KD Manandhar, TP Yadav, VK Prajapati, S Kumar, M Rai, A Dube, ...
Journal of Antimicrobial Chemotherapy 62 (2), 376-380, 2008
832008
Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells
R Mukhopadhyay, S Mukherjee, B Mukherjee, K Naskar, D Mondal, ...
International journal for parasitology 41 (13-14), 1311-1321, 2011
672011
Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent
H Imamura, T Downing, F Van den Broeck, MJ Sanders, S Rijal, S Sundar, ...
Elife 5, e12613, 2016
552016
An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis
VK Prajapati, K Awasthi, TP Yadav, M Rai, ON Srivastava, S Sundar
Journal of Infectious Diseases 205 (2), 333-336, 2011
522011
Detection of Leptomonas sp. parasites in clinical isolates of Kala-azar patients from India
P Srivastava, VK Prajapati, M Vanaerschot, G Van der Auwera, ...
Infection, Genetics and Evolution 10 (7), 1145-1150, 2010
462010
Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian subcontinent?
MR Perry, S Wyllie, VK Prajapati, J Feldmann, S Sundar, M Boelaert, ...
PLoS neglected tropical diseases 5 (9), e1227, 2011
432011
Evaluation of blood agar microtiter plates for culturing leishmania parasites to titrate parasite burden in spleen and peripheral blood of patients with visceral leishmaniasis
R Maurya, S Mehrotra, VK Prajapati, S NylÚn, D Sacks, S Sundar
Journal of clinical microbiology 48 (5), 1932-1934, 2010
422010
Circulating MicroRNAs: potential and emerging biomarkers for diagnosis of human infectious diseases
P Verma, RK Pandey, P Prajapati, VK Prajapati
Frontiers in microbiology 7, 1274, 2016
412016
Unusual case of resistance to amphotericin B in visceral leishmaniasis in a region in India where leishmaniasis is not endemic
P Srivastava, VK Prajapati, M Rai, S Sundar
Journal of clinical microbiology 49 (8), 3088-3091, 2011
402011
Molecular docking and in vitro antileishmanial evaluation of chromene-2-thione analogues
RK Verma, VK Prajapati, GK Verma, D Chakraborty, S Sundar, M Rai, ...
ACS medicinal chemistry letters 3 (3), 243-247, 2012
372012
Drug targeting to infectious diseases by nanoparticles surface functionalized with special biomolecules
S Sundar, V Kumar Prajapati
Current medicinal chemistry 19 (19), 3196-3202, 2012
302012
Brief Definitive Report: Human visceral leishmaniasis is not associated with expansion or accumulation of Foxp3+ CD4 cells in blood or spleen
R Maurya, R Kumar, VK Prajapati, KD Manandhar, D Sacks, S Sundar, ...
Parasite immunology 32 (7), 479-483, 2010
302010
Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India: a retrospective cohort study
MR Perry, VK Prajapati, J Menten, A Raab, J Feldmann, D Chakraborti, ...
PLoS neglected tropical diseases 9 (3), e0003518, 2015
282015
In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis
VK Prajapati, S Sharma, M Rai, B Ostyn, P Salotra, M Vanaerschot, ...
The American journal of tropical medicine and hygiene 89 (4), 750-754, 2013
272013
In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis—status of newly introduced drugs
VK Prajapati, S Mehrotra, S Gautam, M Rai, S Sundar
The American journal of tropical medicine and hygiene 87 (4), 655-657, 2012
262012
Perturbed microRNA expression by Mycobacterium tuberculosis promotes macrophage polarization leading to pro-survival foam cell
PK Ahluwalia, RK Pandey, PK Sehajpal, VK Prajapati
Frontiers in immunology 8, 107, 2017
252017
Exploring Leishmania secretory proteins to design B and T cell multi-epitope subunit vaccine using immunoinformatics approach
N Khatoon, RK Pandey, VK Prajapati
Scientific reports 7 (1), 8285, 2017
242017
The system can't perform the operation now. Try again later.
Articles 1–20